Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo light therapy shows promise for Sun-Damaged skin

NCT ID NCT06091215

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of light and laser treatments on 15 adults with skin pigmentation and texture issues from sun damage. Participants received up to two treatments using the Sciton Joule System, which combines broad-based light, fractionated laser, and dual-wavelength laser. Researchers measured changes in brown spots, pores, wrinkles, and texture using a 3D skin analysis system. The goal was to see if this approach could improve the appearance of sun-damaged skin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sciton Joule System (light and laser device)
What this could lead to
If successful, this could lead to a more effective cosmetic treatment for sun spots, uneven texture, and other skin aging signs.
What could go wrong
This was a very small study (15 people) with no control group, so results may not apply to everyone. The treatment is cosmetic and not a cure for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy male and female adults between 20-75 years of age 2. Fitzpatrick skin type 1-4 3. Individual deemed by the Investigator to benefit from skin resurfacing treatment(s) 4. Individuals willing to withhold aesthetic therapies that may potentially impact results to the treatment areas for the duration of the study 5. Women of childbearing potential: 5.1. will be asked to agree to a pregnancy test before their screening visit in clinic 5.2. must use an acceptable method of birth control * Hormonal contraception (oral, injected, implanted, patch or vaginal ring) * Barrier method with spermicide: condom or occlusive cap with spermicidal foam/gel/cream/suppository * Intrauterine device (IUD) * Surgical Sterilization (e.gh., vasectomy, tubal occlusion, hysterectomy, bilateral salpingectomy/oophorectomy) * Abstinence from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject. Periodical abstinence and withdrawal methods are not acceptable forms of contraception. 6. Individuals who can read, speak, write and understand English and who are willing to provide written informed consent. 7. Individuals willing to sign a photography release with the understanding that their photos may be used during presentations at national conferences and/or published in journals 8. Individuals willing and able to cooperate with all study requirements for the duration of the study. Exclusion Criteria: 1. Fitzpatrick skin type V-VI 2. Known allergies to general skin care products 3. Sensitivity to topical local anesthetic 4. Current or recent history of skin diseases: • Systemic granulomatous disease, either active or inactive, (e.g., Sarcoid, Wegener's, TB, etc) or connective tissue diseases (e.g., lupus, dermatomyositis, etc.) 5. Significant scars in the treatment area: * Severe or cystic and clinically significant acne or acne scars on the areas to be treated * Current or history of hypertrophic scarring or keloid scars 6. Tattoos in the area to be treated 7. Observable suntan, nevi, excessive hair, etc., or other dermal conditions that might influence study results on the face in the opinion of the Investigator 8. Individuals who currently have cancerous or pre-cancerous lesions in the area to be treated 9. Individuals with skin pathology and/or pre-existing dermatologic condition that the Investigator deems inappropriate for participation or could interfere with outcomes of the study, such as: psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, etc. 10. History of chronic drug or alcohol use 11. Recent aesthetic treatments: * \<4 weeks of microdermabrasion or glycolic acid treatment to the treatment area or who plan to have this treatment during the study * \<2 weeks of any type of injectable filler * \<1 week of neurotoxin's * \<6 months of ablative resurfacing laser treatments * \<6 months of non-ablative, rejuvenative laser or light treatment * \<3 months of chemical peels or dermabrasion 12. Use of the following prescription medications: * \<6 weeks of Accutane or other systemic retinoids on the treatment area * \<4 weeks of topical retinoids * \<4 months of prescription strength lightening medications (e.g., hydroquinone, tretinoin, AHA, BHA, poly-hydroxy acids, 4-hydroxyanisole alone or in combination with tretinoin) * \<2 weeks of anti-wrinkle or skin lightening or topical systemic medication known to affect skin aging or dyschromia (e.g., alpha/beta/polyhydroxy acids, Vitamin C, soy, Q-10; hydroquinone, etc.,), TEGO, Cosmo C250, gigawhite, lemon juice extract (topically), or embilica extract * Antiplatelet agents/anticoagulant (Coumadin, Heparin, Plavix, chronic NSAID use) * Psychiatric drugs that would impair the subject from understanding protocol requirements or understanding and signing the ICF. 13. Individuals who are pregnant or planning to become pregnant during the course of the study 14. Immunocompromised individuals or those currently using immunosuppressive medications and/or radiation 15. Individuals with uncontrolled disease such as asthma, diabetes, hyperthyroidism, medically significant hypertension, or hypothyroidism. 16. Individuals with any planned surgeries, overnight hospitalization, and/or invasive medical procedures planned during the course of the study. 17. Individuals who, in the Investigator's opinion, have a history of poor cooperation, unreliability or noncompliance with medical treatment. 18. Individuals who are unable to understand instructions or give informed consent 19. Individuals who have physical or psychological conditions which, in the opinion of the Investigator, makes them unable to complete the study per protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pigment skin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States